Home | Life Sciences Intellectual Property Review
Jan 2, 2025 · Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone.
Latest News & Features | Life Sciences Intellectual Property Review
Dec 24, 2024 · Dispute stems from Amneal’s efforts to market generic version of Teva’s inhaler for treating asthma | Precedential decision could restrict how brand-name pharmaceutical companies use the Orange Book to extend market exclusivity.
Outlook for 2025: how Trump and the USPTO will affect life …
Jan 2, 2025 · Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas | Life Sciences Intellectual Property Review
18 July 2024 Guidance says use of AI in inventing does not affect how patent claims are assessed for eligibility | Emphasis placed on evaluating inventions themselves rather than the method of creation | Updates include new examples to …
Biotechnology | Life Sciences Intellectual Property Review
16 December 2024 A Delaware jury unanimously sided with Sanofi-owned biotech Inhibrx, clearing it of trade secrets misappropriation claims. Amy Candido of Wilson Sonsini shares insights into the defence strategy that led to the win.
Unified Patent Court | Life Sciences Intellectual Property Review
The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills.
GSK triumphs in EPO appeal, revoking Pfizer patent
Nov 14, 2024 · European patent related to an inhaler revoked following successful appeal by GSK | Ruling comes after a series of challenges over novelty and inventive step | Decision further intensifies ongoing patent disputes between the pharma giants.
About | Life Sciences Intellectual Property Review
About. Life Sciences Intellectual Property Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.From gene patents to stem cell research, we hope to provide the best news and analysis. For information about Single Licence and Corporate Licence subscription options, please contact Adrian Tapping: [email protected] ...
Europe | Life Sciences Intellectual Property Review
9 May 2024 10x Genomics injunction showed the need to take the court ‘really seriously’ says US lawyer | With a focus on efficiency and plaintiff-friendly measures, the UPC's impact on patent valuations and litigation strategies is becoming increasingly apparent, at LSPN Spring.
LSPN Fall: Why Big Pharma is facing 'a balancing act'
Oct 17, 2024 · As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies.